In Q42017, ISR surveyed outsourcers of small molecule API and outsourcers of small molecule drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show use of preferred providers is more common for small molecule API than small molecule drug product manufacturing (52% vs. 45%). To learn more, follow the links to the Small Molecule API and the Small Molecule Drug Product report previews.   View File